Drug intelligence / Profile preview

AC-73

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

AC-73 is a first-in-class, specific, orally active small-molecule inhibitor of cluster of differentiation 147 (CD147), also known as basigin or EMMPRIN. It functions by specifically disrupting CD147 dimerization, which is implicated in tumor metastasis and progression. Preclinical studies have shown that AC-73 can inhibit hepatocellular carcinoma metastasis by targeting CD147-mediated signaling pathways[1][2]. The compound represents a novel approach for anti-cancer therapy, particularly in the context of metastatic disease.

Other names: AC73AC-73AC 73

Targets

BSG (Basigin)

Beyond the preview

Go deeper on AC-73.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC-73.

Explore the full profile